FilingReader Intelligence
Alphamab Oncology sets RMB10.2m technology development payment terms
August 18, 2025 at 10:49 AM UTC•By FilingReader AI
Alphamab Oncology will pay RMB3.1m upfront to Suzhou Alphamab for their technology development collaboration, with the remaining RMB7.2m disbursed across four milestone payments.
The company is not required to make additional payments if technical results are not delivered by July 31, 2028.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:9966•Hong Kong Exchange
News Alerts
Get instant email alerts when Alphamab Oncology publishes news
Free account required • Unsubscribe anytime